There is disagreement in the literature as to whether lincomycin is primarily a bacteriostatic or a bactericidal agent against gram-positive cocci and also regarding the levels of activity of this agent against susceptible microorganisms. These questions were examined in a study of In contrast to the above reports, Bals and Bratu (1), using a technique in which antibiotic was diluted in solid medium rather than in broth, found 0.1 to 1.0 ,ug of lincomycin per ml to be totally bacteriostatic for 95 of 100 strains of coagulase-positive staphylococci, with 0.5 ,g/ml being markedly bacteriostatic for 98 strains. Similar results were reported by McCall et al. (9) who, using the inocula-replicating method of Steers et al. (10) 
There is disagreement in the literature as to whether lincomycin is primarily a bacteriostatic or a bactericidal agent against gram-positive cocci and also regarding the levels of activity of this agent against susceptible microorganisms. These questions were examined in a study of the effect of inoculum size on the results of tube dilution susceptibility determinations with lincomycin against 49 1.56 Ag/ml; median MBC, 12.5 ,g/ml). There were further decreases in inhibitory levels and significant losses of bactericidal activity when inocula containing more than 107 cells were tested (median MIC, 3 .13 ug/ml; median MBC > 100 Ag/ml). Similar measurements with streptococci and pneumococci revealed a lesser effect of inoculum size. The mean MBC value for a-hemolytic streptococci increased from 0.40 to 1.05 ;4g/ml with an increase in inocula from 104 to 10 provided a standard containing 1,000 ,Ag of active lincomycin per ml. Serial dilutions of lincomycin containing from 100 to 0.10 (0.098) ,ug/ml were prepared in sterile M-3.
Tests were performed as follows. Five dilution series of lincomycin were prepared for each organism to be tested, with one drug dilution series being employed for each of the five inoculum dilutions. Each tube of diluted drug, in a volume of 1.0 ml, was inoculated with 0.03 to 0.05 ml of diluted bacterial suspension; separate drug-free growth controls were included for each inoculum dilution. The inoculated tubes were incubated for 24 hr at 37 C.
MIC values were determined by visual inspection with the aid of an agglutination viewer (Clay-Adams, no. A-2330). The MIC value for a particular test was the lowest concentration of drug showing no visible sediment at the bottom of the tube. Minimum bactericidal concentration (MBC) was determined by plating approximately 0.05 ml from each tube of a test series showing no visible growth, as well as the first tube showing growth, on either Trypticase Soy Agar or blood-agar plates which were then incubated at 37 C for 24 to 48 hr. The MBC value for a particular test was the lowest concentration of drug which on subsequent plating yielded three or less colonies. Data were rejected in all cases in which the drug-free control tube for a particular dilution of inoculum remained free of growth after 24 hr of incubation.
Disc susceptibility determinations. All isolates were tested qualitatively by using standard 2-,ug lincomycin susceptibility discs with Trypticase Soy Agar. Broth cultures diluted to a transmission of 90% (as prepared above) were used for inocula. Zones of inhibition were measured after 20 to 24 hr of incubation at 37 C by use of a dial-type metric micrometer.
REsuLTs
Effect of inoculum size on the bacteriostatic and bactericidal actions of lincomycin against 49 strains of S. aureus. No significant effect of inoculum size on the bacteriostatic action of lincomycin against S. aureus was observed when tested with inocula containing 105 cells per ml or less (Fig. 1, Table 1 ). The mean MIC for lincomycin, when tested against 40 of the 49 strains of S. aureus, increased from 0.97 ,ug/ml to 1.50 Ag/ml, with an increase in inoculum size from 108 to 105 cells per ml (Table 3) . Of the 49 strains, 40 were tested with lot XB 591-E7 of the diagnostic lincomycin standard. The remaining nine strains were studied earlier by using lot no. WB410-L5 and are excluded from the initial presentation of MIC and MBC data, although essentially identical results were obtained. The maximum MIC recorded for inocula containing 101 cells per ml was 3.13 ,ug/ml. However, when inocula containing 107 cells per ml or more were tested, a marked decrease in bacteriostatic activity was observed with 6 of the 40 strains (15%), yielding MIC values of 6.25 yg/ml or Results similar to the above were also obtained for six strains of,-hemolytic streptococci ( Table  6 ). The maximum MIC value obtained with inocula containing up to 104 cells per ml was 0.39 ,ug/ml. Except for one strain, for which an MIC of 12.5 ,ug/ml was recorded, no significant increases in inhibitory levels were observed with inocula containing 106 cells per ml. A moderate depression of bactericidal activity of lincomycin against f-hemolytic streptococci also was observed with inocula of increasing density. The maximum MBC value obtained with inocula containing 104 cells per ml was 0.78 ug/ml. Three strains were found to be resistant to 6.25 ,ug/ml or more of lincomycin when inocula containing 101 cells were tested, although none was resistant to more than 12.5 ,ug/ml.
Only two strains of pneumococci were tested in this study. Neither of these showed a signifi- cant depression of bacteriostatic activity or bactericidal action of lincomycin with increased inoculum sizes (Table 7) . DIscUSSION The data reported here clearly demonstrate the degree to which experimental conditions can alter the results of bacterial susceptibility testing with lincomycin and gram-positive cocci including, specifically, staphylococci. This is of particular significance in light of the fact that, in most laboratories, determinations of minimal bacteriostatic or bactericidal concentrations are performed primarily to provide the clinician with comparative susceptibility data for several antibiotics upon which he can base his decision as to choice of drug in a specific clinical situation. Any condition inherent within a particular test procedure which might prejudice the results and, therefore, therapeutic decisions based upon these results, must be identified and eliminated. 
